🇺🇸 FDA
Pipeline program

CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL

D781PC00001

Phase 3 small_molecule active

Quick answer

CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL for Advanced HER2-expressing Biliary Tract Cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Advanced HER2-expressing Biliary Tract Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials